Harnessing Immunotherapy for Hepatocellular Carcinoma: Principles and Emerging Promises

Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises

HCC is considered as one of the leadin causes of death worldwide, with the ability of resistance towards therapeutics. Immunotherapy, particularly ICI…

Dual TIGIT and PD-1 Blockade with Domvanalimab Plus Zimberelimab in Hepatocellular Carcinoma Refractory to Anti-PD-1 Therapies: The Phase II LIVERTI Trial

Investigators conducted the Phase II LIVERTI trial testing domvanalimab, a monoclonal Fc-silent anti-TIGIT antibody, plus zimberelimab, an anti-PD-1 antibody, in immunotherapy refractory HCC. [Nature Communications] Full Article